Salvage Regimens in Multiple Myeloma Patients Double Refractory to Lenalidomide and MoAbs: Evidence From Real World Experience
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
⁃ Phase I
• Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme
• Patients aged ≥ 18 years
• Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data
⁃ Phase II
• Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes
• Patients aged ≥ 18 years
• Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data
Locations
Other Locations
Italy
Irccs San Matteo Pavia
RECRUITING
Pavia
Time Frame
Start Date: 2023-08-21
Estimated Completion Date: 2028-08-21
Participants
Target number of participants: 100
Related Therapeutic Areas
Sponsors
Leads: Fondazione IRCCS Policlinico San Matteo di Pavia